NCT03387137View on ClinicalTrials.gov

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

November 22, 2019

Study Completion Date

May 31, 2021

Conditions
RSV Infection
Interventions
BIOLOGICAL

RSV 6120/∆NS2/1030s

Delivered as nose drops

BIOLOGICAL

Placebo

Delivered as nose drops

Trial Locations (1)

21205

Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03387137 - Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children | Biotech Hunter | Biotech Hunter